A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study

Publication | Open Access

DOI Full Paper Access

262

Citations

References

2015

Year

Robert L. Coleman, Michael W. Sill, Katherine M. Bell‐McGuinn, Carol Aghajanian, Heidi J. Gray, Krishnansu S. Tewari, Stephen C. Rubin, Thomas Rutherford, John K. Chan, Alice P. Chen,

Gynecologic Oncology

Brca2 MutationPhase Ii EvaluationGastrointestinal OncologyMedicineGynecologyPathologyCancer TreatmentOncologyRadiation OncologyMolecular OncologyGermline Brca1Ovarian Cancer